BiO€QUITY Europe on 17-19 May 2021

May 17, 2021
No items found.

MNM Diagnostics has developed a unique AI-powered platform allowing for the rapid development of genome-based biomarkers providing an accurate prediction of the treatment outcomes for cancer patients.

To date, we have developed and validated novel biomarker signatures for PARPi and CKD4/6i.

Feel free to request meeting to learn more about MNM Diagnostics during BiO€QUITY Europe conference on 17-19 May 2021

BiO€QUITY Europe on 17-19 May 2021
June 22, 2022

You may also like

Publication in Molecular Diagnosis & Therapy has been just released

MNM Biosciences, in co-operation with leading Polish cancer centers, has recently published a breakthrough publication concerning breast cancer diagnostics.

MNM's platform ARETE works!

MNM's platform ARETE - a proprietary AI technology designed for cancer genomics has been successfully externally validated by one of our Partners.

MNM at the ESMO 2022 Congress

At ESMO 2022 Congress in Paris the era of AI deployment continues.

MNM Bioscience eyes cancer drug target discovery based on its AI algorithms

MNM Bioscience began as a bioinformatics company that curates data and then builds artificial intelligence-based algorithms, but it is now looking to branch out into oncology drug target discovery.